How does sotyktu work (mechanism of action)?
Sotyktu is an oral medicine that targets the immune signaling pathway driven by Janus kinases (JAKs), specifically JAK1 and JAK2. By blocking these kinases, it reduces downstream inflammatory signals that contribute to immune overactivity and symptoms in the conditions it is used to treat. [1]
What immune pathway does it block?
JAK1 and JAK2 transmit signals from cytokine receptors to the cell nucleus, where inflammatory gene programs are turned on. When sotyktu inhibits JAK1/2, fewer inflammatory signals reach that step, which helps lower inflammation. [1]
How does blocking JAK1/2 translate into symptom improvement?
Many inflammatory diseases involve cytokines that rely on JAK-mediated signaling. Reducing that signaling can decrease immune cell activation and inflammation, which is intended to improve disease signs and symptoms over time. [1]
What does that mean for side effects and risks?
Because JAK1/2 inhibition can affect immune pathways more broadly than a single cytokine, it can change the body’s ability to fight infections and can lead to other class-related effects. The specific risks depend on the treated condition and the patient’s health history. [1]
How fast does it start working?
The medication can begin altering immune signaling soon after dosing, but symptom improvement typically occurs over weeks rather than immediately. The exact timeline varies by condition and individual response. [1]
Sources
[1] https://www.sotyktu.com/ (official Sotyktu information)